company background image
4114 logo

Synmosa Biopharma TPEX:4114 Stock Report

Last Price

NT$39.75

Market Cap

NT$15.2b

7D

-0.6%

1Y

0.9%

Updated

12 Jul, 2024

Data

Company Financials

Synmosa Biopharma Corporation

TPEX:4114 Stock Report

Market Cap: NT$15.2b

4114 Stock Overview

A specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan.

4114 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends3/6

Rewards

Risk Analysis

No risks detected for 4114 from our risk checks.

Synmosa Biopharma Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Synmosa Biopharma
Historical stock prices
Current Share PriceNT$39.75
52 Week HighNT$43.70
52 Week LowNT$34.90
Beta0.27
11 Month Change-2.93%
3 Month Change1.66%
1 Year Change0.91%
33 Year Change109.08%
5 Year Change116.87%
Change since IPO522.10%

Recent News & Updates

Recent updates

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Apr 04
Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Mar 08
If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 31
Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05
Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 09
Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Shareholder Returns

4114TW PharmaceuticalsTW Market
7D-0.6%-3.7%3.4%
1Y0.9%16.6%41.1%

Return vs Industry: 4114 underperformed the TW Pharmaceuticals industry which returned 16.6% over the past year.

Return vs Market: 4114 underperformed the TW Market which returned 41.1% over the past year.

Price Volatility

Is 4114's price volatile compared to industry and market?
4114 volatility
4114 Average Weekly Movement1.9%
Pharmaceuticals Industry Average Movement4.5%
Market Average Movement4.8%
10% most volatile stocks in TW Market8.6%
10% least volatile stocks in TW Market2.2%

Stable Share Price: 4114 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4114's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1980n/aChih-Hui Linwww.synmosa.com.tw

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, hormones, and other forms.

Synmosa Biopharma Corporation Fundamentals Summary

How do Synmosa Biopharma's earnings and revenue compare to its market cap?
4114 fundamental statistics
Market capNT$15.19b
Earnings (TTM)NT$650.35m
Revenue (TTM)NT$5.16b

23.4x

P/E Ratio

2.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4114 income statement (TTM)
RevenueNT$5.16b
Cost of RevenueNT$2.99b
Gross ProfitNT$2.18b
Other ExpensesNT$1.53b
EarningsNT$650.35m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.70
Gross Margin42.16%
Net Profit Margin12.59%
Debt/Equity Ratio31.2%

How did 4114 perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

35%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.